key: cord-0914486-ncyusymj authors: Lubin, Joseph H.; Zardecki, Christine; Dolan, Elliott M.; Lu, Changpeng; Shen, Zhuofan; Dutta, Shuchismita; Westbrook, John D.; Hudson, Brian P.; Goodsell, David S.; Williams, Jonathan K.; Voigt, Maria; Sarma, Vidur; Xie, Lingjun; Venkatachalam, Thejasvi; Arnold, Steven; Alfaro Alvarado, Luz Helena; Catalfano, Kevin; Khan, Aaliyah; McCarthy, Erika; Staggers, Sophia; Tinsley, Brea; Trudeau, Alan; Singh, Jitendra; Whitmore, Lindsey; Zheng, Helen; Benedek, Matthew; Currier, Jenna; Dresel, Mark; Duvvuru, Ashish; Dyszel, Britney; Fingar, Emily; Hennen, Elizabeth M.; Kirsch, Michael; Khan, Ali A.; Labrie‐Cleary, Charlotte; Laporte, Stephanie; Lenkeit, Evan; Martin, Kailey; Orellana, Marilyn; Ortiz‐Alvarez de la Campa, Melanie; Paredes, Isaac; Wheeler, Baleigh; Rupert, Allison; Sam, Andrew; See, Katherine; Soto Zapata, Santiago; Craig, Paul A.; Hall, Bonnie L.; Jiang, Jennifer; Koeppe, Julia R.; Mills, Stephen A.; Pikaart, Michael J.; Roberts, Rebecca; Bromberg, Yana; Hoyer, J. Steen; Duffy, Siobain; Tischfield, Jay; Ruiz, Francesc X.; Arnold, Eddy; Baum, Jean; Sandberg, Jesse; Brannigan, Grace; Khare, Sagar D.; Burley, Stephen K. title: Evolution of the SARS‐CoV‐2 proteome in three dimensions (3D) during the first 6 months of the COVID‐19 pandemic date: 2021-10-09 journal: Proteins DOI: 10.1002/prot.26250 sha: 5f4f19d18ff1538a2cd24c77e523cef4f2603a3e doc_id: 914486 cord_uid: ncyusymj Understanding the molecular evolution of the SARS‐CoV‐2 virus as it continues to spread in communities around the globe is important for mitigation and future pandemic preparedness. Three‐dimensional structures of SARS‐CoV‐2 proteins and those of other coronavirusess archived in the Protein Data Bank were used to analyze viral proteome evolution during the first 6 months of the COVID‐19 pandemic. Analyses of spatial locations, chemical properties, and structural and energetic impacts of the observed amino acid changes in >48 000 viral isolates revealed how each one of 29 viral proteins have undergone amino acid changes. Catalytic residues in active sites and binding residues in protein–protein interfaces showed modest, but significant, numbers of substitutions, highlighting the mutational robustness of the viral proteome. Energetics calculations showed that the impact of substitutions on the thermodynamic stability of the proteome follows a universal bi‐Gaussian distribution. Detailed results are presented for potential drug discovery targets and the four structural proteins that comprise the virion, highlighting substitutions with the potential to impact protein structure, enzyme activity, and protein–protein and protein–nucleic acid interfaces. Characterizing the evolution of the virus in three dimensions provides testable insights into viral protein function and should aid in structure‐based drug discovery efforts as well as the prospective identification of amino acid substitutions with potential for drug resistance. RNA virus genomes of all known single-stranded RNA viruses. Their RNA-dependent RNA polymerases act together with RNA helicases and proofreading exonucleases to carry out efficient and relatively faithful copying of the lengthy genome. 2 Proofreading notwithstanding, coronavirus genome replication is not perfect, and coronaviruses do evolve as they passage serially from one host to the next. Today in the time of COVID-19, genome sequence-based "fingerprinting" of the virus in near real time has provided very detailed accounts of how the virus has moved around the globe since late 2019 as infected individuals, many of them asymptomatic, traveled from continent to continent. 3, 4 Viral genome fingerprinting has also enabled detailed analyses of the impact of amino acid changes in particular proteins that modulate infectivity, etc. (e.g., 5 Preparedness against future coronavirus pandemics requires an understanding of the conservation and mutability of viral proteins that are drug design targets. For example, a key coronaviral enzyme is nonstructural protein 5 (nsp5 or main protease or Mpro), which is highly conserved across all known coronaviruses. SARS-CoV-2 nsp5 is 95% identical in amino acid sequence to that of its SARS-CoV-1 counterpart and highly structurally similar ( Figure 1 ). 3D structures of nsp5 are conserved among all known coronaviruses. We had every opportunity in the wake of the SARS-CoV-1 epidemic to discover and develop a drug targeting SARS-CoV-1 nsp5 (and effective against other coronavirus main proteases). Structure-guided approaches using PDB ID 1Q2W 6 and the many structures of SARS-CoV-1 nsp5 subsequently released by the PDB would almost certainly have yielded one (possibly multiple) potent and selective enzyme inhibitor(s) with good druglike properties and an acceptable safety profile. A safe and effective drug targeting SARS-CoV-1 nsp5 would almost certainly be working today for SARS-CoV-2. 7 Looking ahead, structure-based drug design efforts in academia and industry are likely to yield several new drugs targeting nsp5 and other key viral proteins. An understanding of viral evolution will be essential for ensuring the effectiveness of these drugs, and potential combinations in treating SARS-CoV-2 infections. Viral evolution is shaped by the interplay of mutational tolerance and selection pressures due to vaccines or drugs. For example, use of drugs targeting viral proteases of HCV and HIV has led to the emergence of drug resistance mutations (DRMs). DRMs maintain nativelike substrate processing but abolish or significantly diminish drug binding, thereby escaping drug action and gaining an evolutionary advantage. DRMs arise because of the mutational tolerance of the active site residues of viral proteases: in the absence of the drug, there is little evolutionary disadvantage to DRMs, and they simply lurk in the population at low levels until selection pressure is applied. Because DRMs are selected from the pool for pre-existing diversity of viral variants, it is important to understand existing diversity of protein variants in the population, and test drug candidates against such variants to minimize the risk of DRM emergence. Identifying the list of DRMs associated with each drug would enable personalized tailoring of drug cocktails, such that probability of acquiring multiple DRMs can be minimized. DRMs identified in SARS-CoV-2 drug targets may also be present in novel coronaviruses that cross the species barrier. Effective emergency countermeasures administered to prevent future pandemics would, thus, also benefit from an understanding of the DRM landscape of existing therapeutics. Structure-based modeling of existing variants in the population is expected to aid prospective identification of DRMs. F I G U R E 1 (A) Ribbon representation of the experimental structure of SARS-CoV-2 nsp5 (PDB ID 6LU7 8 ), with color coding magenta (α-helices), cyan (β-sheets), and gold (loops) overlaid with SARS-CoV-1 nsp5 (PDB ID 1Q2W 6 ), colored in green. Substrate analog inhibitor present in PDB ID 6LU7 is shown as an atomic stick figure with atom color coding white (carbon), red (oxygen), and blue (nitrogen). (B) The active site of both proteases, with the catalytic dyad (H41 and C145 in 6LU7) shown, with 6LU7 in gold and 1Q2W in gray Herein, we report a comprehensive study of how the SARS-CoV-2 proteome ( Figure 2 ) evolved in 3D during the first 6 months of the pandemic between late 2019 and June 25th, 2020. We combined viral genome sequence data assembled by GISAID (https://www. gisaid.org), the wealth of experimental 3D structure information for SARS-CoV-2 and other coronavirus proteins available from the openaccess Protein Data Bank or PDB, [9] [10] [11] and computed structural models in cases where experimentally-determined structures were not available. Viral genome sequencing and alignments of more than 48 000 individual isolates revealed protein sequence variation between December 2019 and late June 2020. We investigated the spatial locations, chemical properties, and structural and energetic impacts of the observed amino acid changes with reference to the original viral genome/ proteome sequence publicly released in January 2020. Every one of the 29 SARS-CoV-2 study proteins listed in Table 1 underwent changes in amino sequence, generating an average of approximately one unique sequence variant (USV) per study protein amino acid residue (lowest: nsp10 at $0.59 USVs/residue; highest: Orf3a at $2.46 USVs/residue). Protein sequence differences were entirely restricted to nonsynonymous changes in one or more residues. No insertions or deletions were detected in any of the 29 study proteins. Most USVs reflect a single amino acid change in the protein sequence ($66.8%). Smaller proportions of the USVs showed accumulation of two ($25.4%), three ($6.8%), four ($0.8%), or rarely five or more ($0.2%) amino acid substitutions. Where multiple substitutions were observed in a study protein USV, visual inspection of GISAID metadata typically revealed that they accumulated serially, but no systematic effort was made to track sequence changes as a function of sample collection date or geographic location. The modest degree of amino acid sequence variation observed for each of the 29 study proteins analyzed herein is consistent with previous studies of coronavirus evolution, which underscore the importance of the 3 0 -to-5 0 exoribonuclease activity of nsp14 (reviewed in 2 ). In contrast, RNA viruses that do not possess proofreading enzymes (e.g., hepatitis C virus) exhibit significantly higher rates of amino acid substitution. 12 F I G U R E 2 Architecture of the SARS-CoV-2 genome and proteome, including nsps derived from polyproteins or pp1a and pp1ab (shades of blue), virion structural proteins (pink/purple), and open reading frame proteins (Orfs, shades of green). Polyprotein cleavage sites are indicated by inverted triangles for Papain-like Proteinase (PLPro, black) and the Main Protease (nsp5, blue). The double-stranded RNA substrate-product complex of the RNA-dependent RNA polymerase (shown as the nsp7-nsp8 2 -nsp12 heterotetramer and separately with only nsp12) is color coded (yellow: product strand, red: template strand). Transmembrane portions of the Spike S-protein are shown in cartoon form (pink). The source of the structural models used for analyses for all study proteins are indicated (experimentally-determined, computational homology model, or de novo predicted model) Experimental structures or computed 3D structural models were assembled for all 29 study proteins and their respective USVs (see Section 4) . For each study protein, we identified amino acid substitutions mapping to sites in the polypeptide chain buried in the hydrophobic core, exposed on the macromolecule surface, and present in the "boundary" layer between the core and the surface ( Table 2) . Not surprisingly, most of the amino acid substitutions occur on the protein surface ($53.0%) or within the boundary layer ($38.3%). Very few occur in the protein core ($8.7%). Characterization of the nature of each substitution (conserved, nonconserved) revealed that nonconservative amino acid changes were common ($64.3%), albeit less so if they occurred in the core ($54.3%) or the boundary layer ($55.0%), rather than on the protein surface ($69.1%). (N.B. A minority of USVs for some study proteins could not be modeled in 3D due to incomplete structural information.) To further examine the types of amino acid changes in the viral proteome, we generated location-based substitution matrices from the observed USVs for each study protein and for the entire viral proteome ( Figure 3 ). Substitutions to or from all 20 amino acids were changes (e.g., Proline to Aspartate) were also observed. The energetic impact of observed amino acid substitutions for each unique sequence variant of each study protein was calculated using Rosetta ( whereas core residues exhibit a wider distribution with higher positive <ΔΔG App > values. 15 Such asymmetric distributions were also found for lattice model proteins, and were recently shown to arise from first-principle statistical mechanical considerations and a sufficiently large amino acid alphabet size. 16 similarly good fits for bi-Gaussian functions for globular study proteins. Robustness with respect to destabilizing effects of amino acid changes both limits and promotes viral evolution. It is, therefore, remarkable that the observed variation in the SARS-CoV-2 proteome over the first 6 months of the pandemic follows this universal trend, speaking perhaps to the relative rapidity of viral evolution due to large population sizes and imperfect replication machinery. The sections that follow provide more detailed results and discussion pertaining to USVs identified for 13 of the 29 SARS-CoV-2 study pro- 22 while S861 may be involved in a steric clash with the 1 0 -CN group of remdesivir, possibly perturbing the position of the RNA duplex. 23 Knowledge of structures of remdesivir-RdRp complexes will also provide valuable insights into potential sources of drug resistance. The experimental structure of the RdRp-duplex RNA complex (PDB ID 6YYT 21 ) was used for evolutionary analyses of nsp7, nsp8, and nsp12 ( Figure 5A ,B). Each protomer is considered in turn below. substitutions were unique to that USV, suggesting that they are both the result of sequencing artifacts. The vast majority of the USVs (83%) were estimated to be moderately less stable than the reference sequence (<ΔΔG App > $ +7.6 REU). In fewer than 4% cases, the estimated change in apparent free energy of ( Figure 5C ). It is remarkable that all six of these residues are oriented toward the hydrophobic core of the protein, away from the active site, and should, therefore, not disrupt catalysis. No substitutions were observed for nsp12 residues that interact directly or via bridging water molecules with remdesivir ( Figure 5C ; K545, R553, D623, N691, D760, S759, D760). The four protomers forming the RdRp heterotetramer bury significant numbers of residues within the various protein-protein interfaces. It is, therefore, difficult to be certain that a distal substitution might not have a steric influence on one or more of these interfaces. Below, we enumerate substitutions with the potential for direct effects on interfacial contacts. Eleven substitutions involving the following six nsp7 residues could affect binding to nsp12: K7, L14, S15, S26, L40, and L41. Seven No nsp8 D163 substitutions were identified. The contact surface of nsp7 with the second copy of nsp8 is more extensive than with the first. nsp7 substitutions occurring within this inter-subunit interface include residues V6, T9, S15, V16, L20, L28, Because the two nsp8 chains occur in asymmetric environments, a given substitution may alter one interface or the other, or both. Substitutions at 23 sites could affect the nsp8-nsp12 interface for one of the chains (T84, A86, L91, L95, N104, I107, V115, P116, I119, P121, L122, T123, K127, M129, V131, I132, P133, T141, A150, W154 inhibitors. 32 The apo nsp5 structure (PDB ID 6YB7) was used for the evolutionary analyses that follow ( Figure 7A ). Overall substitution trends for nsp5 and energetics analysis results are summarized in Tables 1 and 2 were also substituted, including residues M6, A7, G71, A116, S121, V125, G170, G215, M276, G278, S284, A285, Q299, G302, and T304 , any one of which could affect dimerization. In several cases, Glycine residues at the interface were substituted for larger hydrogen-bonding residues, for example, G71S, G170R, G215R, and G278R. While total stability was reduced, dimer interface stability was increased in all cases except G278R (see Supplementary Table: nsp5 interfacial energies). Interestingly, all substitutions mapping to the dimer interface occurred in USVs lacking any other substitutions. Finally, there were four cases in which substitutions to Proline (a helix breaking amino acid) occurred at positions falling within α-helical or β-strand secondary structural elements (K90P, S123P, A206P, S301P). The latter three represent the most extreme energetic outliers of all USVs, and all four were observed only once in the GISAID dataset. S123P occurs within a β-strand at the dimeric interface near the C-terminus of the homodimeric partner. The calculated destabilization resulting from these substitutions introducing Proline residues in the context of the crystal structure suggest that these variants may lead to backbone structural changes. nsp13 plays a central role in viral replication by unwinding RNA secondary structure within the 5 0 untranslated region of the genome. 33 The enzyme is NTP-dependent and is also known to exhibit 5 0 -triphosphatase activity. nsp13 is most active in the presence of the RdRp, which suggests that the helicase is required for high-efficiency copying of the viral genome. 34 12 Zn ++ -binding residues. A single substitution was observed for Histidine 33 changing to Glutamine (H33Q), which appears unlikely to abrogate binding of Zn ++ . Potentially important amino acid substitutions involve R337 and R339, two residues known to support helicase activity that are positioned at the entrance of the nucleic acid binding channel. Substitutions were observed in the R337L;A362V and R339L USVs. A SARS-CoV-1 R337A;R339A double substitution showed decreased helicase activity. 36 It is, therefore, likely that R337L and R339L substitutions in SARS-CoV-2 nsp13 reduced enzyme activity. Another interesting substitution involves the R567, which is important for NTP hydrolysis in SARS-CoV-1 nsp13. 36 An R567I substitution occurs in the context of the double substitution USV (V456F;R567I; GISAID dataset count = 1) and may reduce SARS-CoV-2 nsp13 helicase activity. The most prevalent RBD substitution is the T478I (count = 57), which is in a portion of a loop that contacts ACE2, though residue 478 does not appear to be in direct contact itself. Interestingly, most substitutions directly interfacing with ACE2 were primarily neutral or destabilizing, with none improving binding affinity by more than À1 REU. It was recognized early in the pandemic that the S-protein possesses a potential furin cleavage site (residue 681-PRRAR/SV-residue687). Furin cleavage is thought to represent another mechanism for transition into a fusion-compatible state, 56 thereby contributing to virulence. However, the virus was still found to be infectious upon deletion of the furin cleavage site, indicating that it may not be required for viral entry 47 but may affect replication kinetics. 56 In that Figure 13 ). The N-terminal seven residues and the C-terminal ten residues were omitted from the homology model, because they were not reported in the SARS-CoV-1 NMR structure. Overall substitution trends for the E-protein and energetics analysis results are summarized in Tables 1 and 2 The SARS-CoV-2 genome resembles a single-stranded cellular messenger RNA, $29.9 kb in length with a 7-methyl-G 5 0 cap, a 3 0 poly-A tail, and more than 10 open reading frames or Orfs (Figure 1 ). Viral proteins are expressed in two ways. Translation of two long polyproteins occurs initially, yielding the machinery required to copy the viral genome. Subsequent expression of multiple sub-genomic mRNAs produces the four structural proteins present in virions and other proteins designated as Orf3a, Orf6, Orf7a, Orf7b, Orf8, Orf9b, Orf14, and possibly the hypothetical protein Orf10. The nonstructural proteins (nsps) are expressed within the shorter polyprotein 1a (pp1a, encompassing nsp1-nsp11) and the longer polyprotein 1ab (pp1ab, encompassing nsp1-nsp16). Both pp1a and pp1ab require two virallyencoded proteases for processing into individual nsp protomers ( Figure 2 ). nsp3 includes a papain-like protease (PLPro) domain, which is responsible for polypeptide chain cleavage at three sites within the N-terminal portions of both polyproteins (dark blue inverted triangles in Figure 1 ). Ten additional polypeptide chain cleavages are carried out by nsp5 (light blue inverted triangles in Figure 2 ), also known as the main protease or the 3C-like protease. The structural proteins present in mature virions include the S-protein (surface spike glycoprotein, responsible for viral entry), the N-protein (nucleocapsid protein), the E-protein (a pentameric ion channel), and the M-protein (a second integral membrane protein found in the viral lipid bilayer). Pre-aligned protein sequences were downloaded in FASTA format from the GISAID website (gisaid.org) 83,84 on June 25th, 2020. Sequence alignments for each of the SARS-CoV-2 proteins (hereafter study proteins) were constructed by removing non-human sequences from the alignment; removing truncated sequences; removing incompletely determined sequences (i.e., those with one or more "X" in lieu of an amino acid one-letter code); and eliminating The RCSB Protein Data Bank web-native molecular graphics tool (Mol* 101 ) was used for visual inspection and comparison of reference and amino-acid-substitute study proteins. Space-filling representation figures were generated using Illustrate. 102 Ribbon/atomic stick figure representation figures were generated using Mol* and PyMOL. 103 PyRosetta 104 was used to analyze each study protein and its observed USVs. All residue pairs with C α -C α distance <5.5 Å were considered neighbors, and residue pairs with C α -C α distance <11 Å were also considered neighbors if their C α -C β vectors were at an angle <75 . Residue layer identifications were performed on reference (rather than substituted) study protein structures, based on side chain neighbors within a cone centered on the C α -C β vector, which is independent of side chain conformation. The Layer Determination Factor (LDF) is defined as LDF = ((cos[θ] + 0.5)/1.5) 2 /(1 + exp[d À 9]), where θ is the angle between the C α -C β vector of a given residue and that of a neighbor, and d is the C α -C α distance between residue and neighbor. LDF is summed over nearby neighbors and if its value is <2, the residue is considered surface. If it is >5.2, the residue is considered core. Otherwise, it is considered boundary. Amino acid substitution conservation was determined by whether a residue change stayed within a residue type group as follows: hydro- Experimental structures and computed structural models of study proteins were prepared for computational analyses using the Rosetta FastRelax protocol, employing atom positional restraints to limit significant changes to backbone geometry. Homo-oligomeric proteins were modeled using the symmetric protein modeling framework in Rosetta. 105 Integral membrane proteins were modeled using Rosetta membrane protein modeling framework. 106 Structural models for study protein USVs were computed by replacing the reference side chain atomic coordinates in the starting model with those of the substituted amino acid(s) and performing three rounds of Monte Carlo optimization of rotamers for all side chains falling within an 8 Å radius of the substitution(s), followed by gradient-based energy minimization of the entire structure, with atom positional restraints to limit significant changes to backbone geometry. Computed structural model optimizations were performed with three different combinations of scoring functions based on previous work, 107 including "hard-hard," indicating that both side chain optimization and structure minimization were performed with default van der Waals repulsion term in the Rosetta scorefunction, "soft-soft" indicating that for both steps, a different scorefunction was used that has dampened van der Waals repulsion (in this case, the backbone was entirely prevented from moving during minimization), and "soft-hard" indicating that the soft-repulsive score function was used for side chain rotamer optimization, while the hardrepulsive scorefunction was used for energy minimization. The scorefunctions used were REF2015 108 Emerging coronaviruses: genome structure, replication, and pathogenesis Coronaviruses Decoding SARS-CoV-2 transmission and evolution and ramifications for COVID-19 diagnosis, vaccine, and medicine Nextstrain: real-time tracking of pathogen evolution Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus Company says it mapped part of SARS virus. The New York Times How to help the free market fight coronavirus Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors Crystallography: protein data bank The Protein Data Bank Protein Data Bank: the single global archive for 3D macromolecular structure data Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Stability of protein structure and hydrophobic interaction Universal distribution of mutational effects on protein stability, uncoupling of protein robustness from sequence evolution and distinct evolutionary modes of prokaryotic and eukaryotic proteins The stability effects of protein mutations appear to be universally distributed Effects of single mutations on protein stability are Gaussian distributed Thermodynamic prediction of protein neutrality Protein stability engineering insights revealed by domain-wide comprehensive mutagenesis The architecture of SARS-CoV-2 transcriptome Structure of the RNA-dependent RNA polymerase from COVID-19 virus Structure of replicating SARS-CoV-2 polymerase Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir Structural basis for RNA replication by the SARS-CoV-2 polymerase A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity The crystal structure of papain-like protease of SARS CoV-2 in complex with PLP_Snyder441 inhibitor 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism Crowdsourcing drug discovery for pandemics Secondary structure of the SARS-CoV-2 5 0 -UTR Mechanism of nucleic acid unwinding by SARS-CoV helicase Structural basis for helicasepolymerase coupling in the SARS-CoV-2 replication-transcription complex Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis Genomic characterization of a novel SARS-CoV-2 Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2 0 -O-methylation by nsp16/nsp10 protein complex High-resolution structures of the SARS-CoV-2 2 0 -O-methyltransferase reveal strategies for structure-based inhibitor design Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2 0 -O-methyltransferase nsp10/nsp16 complex The crystal structure of nsp10-nsp16 heterodimer from SARS-CoV-2 in complex with Sadenosylmethionine Crystal structure of non-structural protein 10 from severe acute respiratory syndrome coronavirus-2 Sitespecific glycan analysis of the SARS-CoV-2 spike Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Controlling the SARS-CoV-2 spike glycoprotein conformation Continuous flexibility analysis of SARS-CoV-2 spike prefusion structures Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor Structural and functional basis of SARS-CoV-2 entry by using human ACE2 SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant Furin cleavage site is key to SARS-CoV-2 pathogenesis Natural polymorphisms are present in the Furin cleavage site of the SARS-CoV-2 spike glycoprotein High-resolution analysis and functional mapping of cleavage sites and substrate proteins of furin in the human proteome The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Coronavirus membrane fusion mechanism offers a potential target for antiviral development Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2 The Sialoside-binding pocket of SARS-CoV-2 spike glycoprotein structurally resembles MERS-CoV Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites Crystal structure of RNA binding domain of nucleocapsid phosphoprotein from SARS coronavirus 2 High-resolution structure and biophysical characterization of the nucleocapsid phosphoprotein dimerization domain from the Covid-19 severe acute respiratory syndrome coronavirus 2 The coronavirus E protein: assembly and beyond A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo Coronavirus envelope protein: current knowledge Structural model of the SARS coronavirus E channel in LMPG micelles Coronavirus E protein forms ion channels with functionally and structurallyinvolved membrane lipids Expression and membrane integration of SARS-CoV E protein and its interaction with M protein The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles Identifying SARS-CoV membrane protein amino acid residues linked to viruslike particle assembly A structural analysis of M protein in coronavirus assembly and morphology Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein Impact of protein data Bank on anti-neoplastic approvals RCSB protein data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering, and energy sciences RCSB protein data bank: enabling biomedical research and drug discovery RCSB protein data bank: sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education Virtual boot camp: COVID-19 evolution and structural biology GISAID: global initiative on sharing all influenza data -from vision to reality disease and diplomacy: GISAID's innovative contribution to global health A new coronavirus associated with human respiratory disease in China Structural characterization of nonstructural protein 1 from SARS-CoV-2. iScience Crystal structure of the ubiquitin-like domain 1 (Ubl1) of Nsp3 from SARS-CoV-2 Molecular basis for ADP-ribose binding to the Mac1 domain of SARS-CoV-2 nsp3 Crystal structure of the nucleic acid binding domain (NAB) of Nsp3 from SARS-CoV-2 SARS-CoV-2 main protease with unliganded active site (2019-nCoV, coronavirus disease 2019, COVID-19) Crystal structure of the SARS-CoV-2 non-structural protein 9 Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2 Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor for human CD14(+) monocytes. iScience Center for Structural Genomics of Infectious Diseases (CSGID) SWISS-MODEL: homology modelling of protein structures and complexes The SARS-unique domain (SUD) of SARS coronavirus contains two macrodomains that bind Gquadruplexes VMD: visual molecular dynamics Scalable molecular dynamics on CPU and GPU architectures with NAMD All-atom empirical potential for molecular modeling and dynamics studies of proteins Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures Illustrate: software for biomolecular illustration The PyMOL molecular graphics system PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta Modeling symmetric macromolecular structures in Rosetta3 An integrated framework advancing membrane protein modeling and design Role of conformational sampling in computing mutation-induced changes in protein structure and stability The Rosetta all-atom energy function for macromolecular modeling and design Protein structure prediction and design in a biologically realistic implicit membrane Evolution of the SARS-CoV-2 proteome in three dimensions (3D) during the first 6 months of the COVID-19 pandemic We thank all the many structural biologists who have deposited coronavirus protein structures to the PDB archive since 2002. We also thank Drs. David Baker and Ivan Anischenko for providing com- The authors declare no competing financial interests.